Do you want to read an article? Please log in or register.
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(24)00208-X
RECOMMENDED
Pulmonary Fibrosis
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T
doi: 10.1016/j.rmed.2025.108080
RECOMMENDED
Pulmonary Fibrosis
Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Sci Rep
Imrei M, Kéri AF, Gács É, Gönczi I, Meláth M, Kosaras É, Demeter B, Péterfia C, Vass K, Székely G, Ocskay K, Párniczky A
doi: 10.1038/s41598-025-86010-1
RECOMMENDED
Pulmonary Fibrosis
Outcomes of a cross-sectional ultrasound- based study of cystic fibrosis related liver disease: A real world experience
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kurkal K, Kuek SL, Herath D, Ong C, Harrison J, Cooney H, Poulter C, Oliver M
doi: 10.1016/j.jcf.2024.06.008
Pulmonary Fibrosis
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Respir Med
Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V
doi: 10.1016/j.rmed.2025.108221
RECOMMENDED
Pulmonary Fibrosis
Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir Rev
Hansen CME, Breukelman AJ, van den Bemt PMLA, Zwitserloot AM, van Dijk L, van Boven JFM
doi: 10.1183/16000617.0060-2024
RECOMMENDED
Pulmonary FibrosisPneumonia
Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution
doi: 10.1016/j.rmed.2025.108087
RECOMMENDED
Further Publications
Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Pediatr Pulmonol
López Cárdenes CM, Merino Sánchez-Cañete A, Vicente Santamaría S, Gascón Galindo C, Merino Sanz N, Tabares González A, Blitz Castro E, Morales Tirado A, Garriga García M, López Rozas M, Ramos Riesgo T, Álvarez Beltrán M, Gutiérrez Martínez JR, Suárez González M, García Romero R, De la Mano Hernández A, Muñoz Codoceo MR, Martín Fernández C, Tutau Gómez C, Torcuato Rubio E, Ortiz Pérez P, Loverdos Eseverri I, García Volpe C, Salcedo Lobato E, Martín Rivada A, Castro Millan AM, Del Brio Castillo R, Sierra San Nicolás S, Murray Hurtado M, Crehuá Gaudiza E, Medina Martínez M, González Jiménez D, y grupo de trabajo de FQ y páncreas de la SEGHNP
doi: 10.1002/ppul.27272
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012